Speaker Profile

President & CEO, Biocept

Mr. Nall has over 30 years of healthcare leadership experience and has been President and CEO of Biocept since 2013. During this time, the company has transitioned from R&D to commercialization of molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis and monitoring of patients with cancer. Most recently, this includes the CNSide™ cerebrospinal fluid assay, designed to aid in the management of cancer that has metastasized to the central nervous system. Mr. Nall previously served in commercial and operational leadership roles at multiple companies, including as General Manager, North America Sales and Marketing for GE Healthcare’s Clarient division, leading all aspects of commercialization including sales, marketing and reimbursement for laboratory services. Prior to Clarient, Mr. Nall served at Impath, Maquet Surgical, Midwest Medical, CVS Specialty Distribution and American Cyanamid.

Cerebrospinal Fluid Assay Aids in Management of Metastatic Cancer with CNS Involvement
Approximately 50% of brain metastases have actionable mutations not detected in the primary tumor. A novel liquid biopsy assay detects and quantifies tumor cells in the cerebrospinal fluid and identifies actionable biomarkers. Recently presented data show the assay identifies actionable HER2 and genetic heterogeneity in patients with breast cancer that has metastasized to the brain.

 Session Abstract – PMWC 2022 Silicon Valley

The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.


  • Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
    Session Chair: Jimmy Lin, Freenome
    - Nicholas Dracopoli, delfi Diagnostics
    - Ash Alizadeh, Stanford
    - Amir Ali Talasaz, Guardant Health
    - Anne-Renee Hartman, Adela
  • How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
    Session Chair: Rebecca Brandes, Agilent
    - Edward Abrahams, PMC
    - Kate Knobil, Agilent
    - Adrian Lee, UPMC
  • The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
    - Alexey Aleshin, Natera
  • Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
    Session Chair: Sam Salman, miR Scientific
    - Frederick Baehner, Exact Sciences
  • The Advantages of Exosomes as a Liquid Biopsy Based Markers
    Session Chair: Johan Skog, Exosome Diagnostics
    - Jamil Azzi, Harvard
    - Dolores Di Vizio, Cedars-Sinai Medical Center
  • The Current Regulatory Landscape of Liquid Biopsy In Oncology (PANEL)
    Session Chair: Deepshikha Bhandari, Grail Bio
    - Seema Singh Bhan, Exact Sciences
    - Ryan Woodhouse, Foundation Medicine
  • Showcase
    - Samuel Levy, Bluestar Genomics
    - Richard Chen, Personalis
    - Michael Nall, Biocept